BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-05-22), Bristol-Myers Squibb Co's current share price is $47.03. Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $20.15. Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio for today is 2.33.
The historical rank and industry rank for Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Bristol-Myers Squibb Co's highest Cyclically Adjusted PS Ratio was 7.00. The lowest was 2.08. And the median was 4.62.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Bristol-Myers Squibb Co's adjusted revenue per share data for the three months ended in Mar. 2025 was $5.491. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $20.15 for the trailing ten years ended in Mar. 2025.
The historical data trend for Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
4.67 | 4.21 | 4.34 | 2.85 | 2.88 |
Bristol-Myers Squibb Co Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2.91 | 2.18 | 2.67 | 2.88 | 3.03 |
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 47.03 | / | 20.15 | |
= | 2.33 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:
For example, Bristol-Myers Squibb Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2025 (Change) | * | Current CPI (Mar. 2025) |
= | 5.491 | / | 134.9266 | * | 134.9266 | |
= | 5.491 |
Current CPI (Mar. 2025) = 134.9266.
Bristol-Myers Squibb Co Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201506 | 2.497 | 100.684 | 3.346 |
201509 | 2.425 | 100.392 | 3.259 |
201512 | 2.544 | 99.792 | 3.440 |
201603 | 2.614 | 100.470 | 3.510 |
201606 | 2.901 | 101.688 | 3.849 |
201609 | 2.932 | 101.861 | 3.884 |
201612 | 3.115 | 101.863 | 4.126 |
201703 | 2.950 | 102.862 | 3.870 |
201706 | 3.118 | 103.349 | 4.071 |
201709 | 3.194 | 104.136 | 4.138 |
201712 | 3.316 | 104.011 | 4.302 |
201803 | 3.166 | 105.290 | 4.057 |
201806 | 3.487 | 106.317 | 4.425 |
201809 | 3.479 | 106.507 | 4.407 |
201812 | 3.649 | 105.998 | 4.645 |
201903 | 3.616 | 107.251 | 4.549 |
201906 | 3.832 | 108.070 | 4.784 |
201909 | 3.676 | 108.329 | 4.579 |
201912 | 4.095 | 108.420 | 5.096 |
202003 | 4.775 | 108.902 | 5.916 |
202006 | 4.476 | 108.767 | 5.553 |
202009 | 4.603 | 109.815 | 5.656 |
202012 | 4.915 | 109.897 | 6.034 |
202103 | 4.889 | 111.754 | 5.903 |
202106 | 5.197 | 114.631 | 6.117 |
202109 | 5.182 | 115.734 | 6.041 |
202112 | 5.396 | 117.630 | 6.189 |
202203 | 5.383 | 121.301 | 5.988 |
202206 | 5.531 | 125.017 | 5.969 |
202209 | 5.223 | 125.227 | 5.628 |
202212 | 5.375 | 125.222 | 5.792 |
202303 | 5.365 | 127.348 | 5.684 |
202306 | 5.341 | 128.729 | 5.598 |
202309 | 5.313 | 129.860 | 5.520 |
202312 | 5.645 | 129.419 | 5.885 |
202403 | 5.865 | 131.776 | 6.005 |
202406 | 6.013 | 132.554 | 6.121 |
202409 | 5.855 | 133.029 | 5.939 |
202412 | 6.080 | 133.157 | 6.161 |
202503 | 5.491 | 134.927 | 5.491 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Bristol-Myers Squibb Co (NYSE:BMY) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher S. Boerner | officer: EVP, Chief Commercial Officer | 21823 30TH DRIVE S, BOTHELL WA 98021 |
Samit Hirawat | officer: Chief Medical Offr., Drug Dev. | BRISTOL-MYERS SQIUBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Samuels Theodore R. Ii | director | 1990 E. GRAND AVE., EL SEGUNDO CA 90245 |
Cari Gallman | officer: EVP, Corporate Affairs | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Ann Powell Judge | officer: SVP, Human Resources | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
Robert M Plenge | officer: EVP, Chief Research Officer | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Rupert Vessey | officer: Pres., Research & Early Dev. | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Adam Lenkowsky | officer: EVP, Chief Commercial Officer | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Giovanni Caforio | officer: EVP & Chief Commercial Officer | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
David V Elkins | officer: EVP, Chief Financial Officer | C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417 |
Deepak Bhatt | director | BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016 |
Sandra Leung | officer: Vice President and Secretary | C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
Sharon Greenlees | officer: SVP & Controller | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Karin Shanahan | officer: EVP, Glob. Prod. Dev. & Supply | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Gregory Scott Meyers | officer: EVP, Chief Digital & Tech Off. | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
From GuruFocus
By GuruFocus News • 04-14-2025
By GuruFocus News • 04-10-2025
By GuruFocus News • 04-19-2025
By GuruFocus News • 04-11-2025
By GuruFocus News • 04-09-2025
By GuruFocus News • 04-08-2025
By Business Wire • 04-14-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 04-09-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.